ARRY-382 is a small molecule and orally available inhibitor designed to target colony-stimulating factor-1 receptor (CSF1R, also known as cFMS). It functions by binding to and inhibiting cFMS tyrosine kinase activity, thereby disrupting CSF-1-mediated signaling that is implicated in tumor cell proliferation and macrophage regulation.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing ARRY-382?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Afatinib D6
pharmaceutical raw material
Gadodiamide
pharmaceutical raw material
Umifenovir hydrochloride
pharmaceutical raw material
Ethyl 6-bromo-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
pharmaceutical raw material
The international HS code for ARRY-382 (CAS 1313407-95-2) is 2933.59.
2933.59
2933 59 95
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide
JUPOTOIJLKDAPF-UHFFFAOYSA-N
CC1=NC(=CC=C1)CN2C3=CC=CC(=C3C(=N2)C4CC4)NC(=O)C5=CN=C6N5C=CC(=C6)OCCN7CCN(CC7)C
Sourcing ARRY-382?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.